Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Alecensa (alectinib) for the Treatment of ALK-positive Non-small Cell Lung Cancer (NSCLC)

Drug (Brand / Generic)

Alecensa / alectinib

Company / Licensee

Roche Group / Chugai Pharmaceutical

Therapy Class

Tyrosine kinase inhibitor (TKI)

Current Indication

ALK-positive non-small cell lung cancer (NSCLC)

Market Sector

Oncology

Development Status

Approved in the US, Europe and Japan
Expand

Go Top